Pre-Screening Explained: What Happens Between Identifying A Patient And Enrolling Them
Clinical trial pre-screening is the early review that asks whether a person might be suitable for a study before the full, protocol-specific screening process begins. A potential participant may still decline contact, fail a formal eligibility check, need further information, or be deferred while a clinical question is clarified.
The practical sequence is usually: define the study criteria, identify a possible match, review limited relevant information, contact the person through an appropriate route, provide study information, obtain informed consent before consented research procedures, complete formal screening, and then confirm eligibility for enrolment or randomisation where applicable. Keeping these stages separate protects patients and gives sponsors a more realistic view of recruitment capacity.
What Is Clinical Trial Pre-Screening?
Pre-screening is a preliminary assessment of whether someone appears to meet broad study requirements and may be interested in hearing more. It can involve a record-based search by an authorised healthcare team, a clinician referral, a registry match, a short questionnaire, or a telephone conversation using basic questions. The exact boundary varies by protocol and governance arrangement.
Pre-screening normally considers information such as the relevant diagnosis, age range, disease stage, prior treatments, current medicines, key comorbidities and broad location or visit requirements. Our guide to the clinical trial screening process describes initial pre-screening through forms, questionnaires or short phone interviews, followed by more detailed checks when appropriate.
The important limitation is that a database match or preliminary conversation does not establish eligibility. Some protocol requirements can only be assessed with current laboratory results, imaging, examination, specialist review, confirmed treatment history or other study-specific assessments. Pre-screening should therefore reduce avoidable work without being presented as a substitute for investigator oversight.
The Eight Stages From Patient Identification To Enrolment
Stage | What happens | What it does not mean |
1. Protocol criteria | The sponsor and study team define inclusion, exclusion, safety and operational requirements. | A broad disease match is not enough. |
2. Potential identification | An authorised GP, specialist, registry or recruitment route finds someone who may fit. | The person has not agreed to participate. |
3. Preliminary review | Relevant available information is compared with broad criteria and obvious conflicts are flagged. | The review is not final eligibility confirmation. |
4. Appropriate contact | The patient receives an invitation or information through an approved, suitable route. | Contact is not consent. |
5. Information and consent | The person considers the study, asks questions and gives informed consent where required before consented procedures. | Consent does not guarantee eligibility. |
6. Formal screening | The site performs protocol-specific history, examination, tests and assessments. | A screening appointment is not automatically enrolment. |
7. Eligibility decision | The investigator or authorised site team confirms eligible, deferred or ineligible status. | A match cannot overrule a safety decision. |
8. Enrolment | The participant completes the study's enrolment steps and may be randomised if the design requires it. | Enrolment is not the same as treatment benefit. |
How Are Potential Participants Identified?
There is no single recruitment route. Potential participants may be identified through a treating clinician, GP patient database search, hospital records, a public trial registry, a patient organisation, advertising, a research volunteer database or a digital notification service. The appropriate route depends on the protocol, the population, the study location and the permissions governing the information.
For UK primary-care recruitment, the GP practice reviews its own records once the study criteria and practical arrangements are clear. This is the model TrialChoices uses. As one of the largest patient recruitment firms in Europe, TrialChoices works with GP practices that collectively care for 5 million UK patients, with a further 9 million reachable through wider Primary Care Network searches. On our GP page, we explain the sequence: we present the opportunity to the practice, the GP chooses whether to opt in, and the practice team reviews its patient data for suitable people before we connect them with the research team.
Because the search runs on live GP records, the starting cohort reflects patients as they are today, not as they were when a static database was last updated. That is how initial cohorts can be identified in hours and days.
A useful pre-screening search is specific enough to identify a meaningful cohort but limited enough to avoid unnecessary disclosure. For example, a cardiovascular study might initially look for a diagnosis, a relevant medication history, an age band and a recent clinical indicator. It would not be appropriate to assume that every record match is suitable for a procedure, a new medicine or a particular trial location without clinical review.
What Information Is Reviewed During Pre-Screening?
The information reviewed should reflect the protocol and the purpose of the early filter. Common categories include:
Diagnosis and disease subtype, stage or severity.
Age, sex where relevant to the protocol, and broad geography.
Prior and current treatments, including washout or treatment-history requirements.
Relevant medicines, allergies and comorbidities.
Recent laboratory, imaging or physiological results when available.
Practical requirements such as visit frequency, travel distance, language support or digital access.
Whether the person may be interested and can be approached through an appropriate route.
The aim is not to collect every possible detail at the first step. Our article on electronic patient data in clinical study recruitment describes filtering records against study criteria to identify potential candidates, with privacy and GDPR compliance built in. In the TrialChoices model, patient information stays within the GP practice or is handled securely by the relevant research organisation; TrialChoices itself does not need access to patient data. Sponsors should still define which fields are necessary, who can see them, how decisions are recorded and when the site must verify the information directly.
What Role Do GPs And Healthcare Professionals Play?
GPs and other healthcare professionals add context that a simple keyword search cannot. They know whether a diagnosis is current, whether a medicine is still being taken, whether a patient is stable enough to consider a referral, and whether contact would be appropriate at that point in care. They can also explain why a research invitation is being offered without implying that the study is suitable or that participation is expected.
GPs are central to UK research because they hold longitudinal information and trusted relationships with their patients. Our article on the future role of GPs in clinical research sets out how GP-led identification, patient explanation and ongoing support fit into the wider recruitment pathway. Most UK clinical research starts and ends with the GP, which is why going direct to primary care removes so many unnecessary steps.
When Does Patient Contact Happen?
Patient contact should happen after the recruitment route, governance arrangements and contact responsibility have been agreed. In some models, the treating clinician or practice team tells the patient about the opportunity. In others, an approved research team contacts someone who has already indicated interest. The person should be given enough information to understand that they are being invited to consider research, not told that they have been accepted.
A good first conversation is proportionate. It explains the study's broad purpose, why the person may be receiving the invitation, what participation could involve, where visits may occur, and how the person can ask questions or decline. It should avoid overstating benefits. Being identified for a trial does not mean the treatment will work, that the person will receive the investigational product, or that they will pass formal screening.
Our patient-selection article emphasises the importance of informed, respectful recruitment and covers physician referrals, registries, healthcare settings, digital notifications and patient organisations as possible routes. Whatever the route, the invitation must be authorised, understandable and appropriate for the individual. When it comes from a patient's own GP, it is also coming from someone they already trust.
How Does Informed Consent Fit Into Pre-Screening?
Informed consent is the person's voluntary decision to take part after receiving understandable information about the study, its procedures, foreseeable risks, potential benefits, data use, alternatives and the right to withdraw. It is not a signature collected to guarantee enrolment. A person may consent to screening and then be found ineligible, or may decide not to continue after learning more.
The Health Research Authority's consent guidance says participant information and consent materials should be appropriate and proportionate, with guidance covering adults, children, young people and adults who cannot consent for themselves. This makes a practical distinction important: a preliminary conversation can establish interest, but the formal consent process must provide the information and documentation required for the study and jurisdiction.
Data protection is related but not identical. HRA guidance explains that consent to participate in research is not necessarily the same as the legal basis for processing personal or special-category health data. Sponsors and healthcare organisations should document both the legal basis for data processing and the confidentiality arrangements that permit the proposed use. See the HRA legal-basis guidance for the distinction.
What Happens During Formal Screening?
Formal screening is the protocol-specific assessment performed by the research site. Depending on the study, it may include a detailed medical-history review, medication reconciliation, physical examination, blood tests, ECG, imaging, genetic testing, questionnaires, specialist review or other baseline measurements. The study team uses the approved protocol and documented procedures to decide whether the person meets the criteria and whether participation is safe and appropriate.
Our screening-process article describes possible outcomes as eligible, deferred or ineligible. Deferral can occur when a temporary factor needs to resolve or when further information is required. A clear reason for each outcome helps the sponsor understand whether recruitment is failing because the population is too small, the criteria are unclear, the data are incomplete, or the operational pathway is creating avoidable losses.
Since 28 April 2026, compliance with the ICH E6(R3) Good Clinical Practice principles has been a legal requirement for UK trials of investigational medicinal products. The guideline places clear responsibilities on investigators and sponsors for participant protection, informed consent, protocol compliance, data and records, and quality management. Pre-screening improves efficiency, but final clinical responsibility always stays with the appropriately qualified study team.
Why Do Identified Patients Not Always Enrol?
There are several legitimate points at which a potential match may leave the pathway. The person may not want to participate, may not respond, or may find the travel and visit schedule unsuitable. A formal test may show that a laboratory value, imaging result or disease measurement falls outside the protocol. A medication or prior treatment may conflict with the study. The investigator may identify a safety concern, or the study may close recruitment before the assessment is complete. Where pre-screening relies on old or third-party records, the information itself may simply be out of date, which is one of the strongest arguments for working from live GP records.
For sponsors, these outcomes should be measured rather than hidden inside a single "recruitment rate". Useful metrics include potential matches, contact and response rates, consent-to-screen conversion, screen failures by criterion, time to screening, and reasons for deferral or ineligibility.
Our multi-site recruitment strategy article recommends combining site feasibility, population data, local healthcare relationships, consistent processes and performance monitoring. The practical extension is to monitor the handoff between stages, not just the final number enrolled.
How Can Sponsors Improve The Pre-Screening Handoff?
Start with a one-page pathway that names the owner, data source, decision and next action at every stage. Then test it with realistic cases, including obvious matches, borderline cases, incomplete records and people who decline. This identifies ambiguity before it becomes a site query or a patient-facing disappointment.
Write preliminary rules in plain language and map each one to the protocol criterion it represents.
Separate information used for an initial match from information requiring formal clinical assessment.
Set an escalation route for uncertain cases instead of asking each practice to interpret the protocol alone.
Give patients clear information about why they were approached and what will happen next.
Track reasons for non-progression by site, criterion, geography and participant group.
Use data-enabled matching with defined governance, human review, audit trails and a plan for missing or inaccurate data.
TrialChoices supports each of these steps. We screen every research partner in detail and share that information with GP practices, every trial we bring to GPs is registered with the appropriate agencies, and our practices only review patient data once a study is confirmed and active. Research teams can find out more on our Researchers page, and GP practices can see how participation works on our GP page.
What Changed In UK Clinical-Trial Practice In 2026?
The amended UK Clinical Trials Regulations came into force on 28 April 2026, alongside the UK implementation of ICH E6(R3). The HRA's reform guidance describes updated responsibilities and terminology, including "participant" rather than the older regulatory term "subject" in relevant contexts, alongside new transparency and consent provisions.
For pre-screening, the practical lesson is that faster recruitment still requires a documented, proportionate and participant-centred pathway. The team must know what can be reviewed before consent, how confidential information is protected, and where final eligibility is confirmed.
Frequently Asked Questions
What happens during clinical trial pre-screening?
A healthcare or research team compares limited relevant information with broad study requirements to decide whether further contact or assessment is appropriate. It may use a record search, clinician referral, questionnaire or short conversation. It does not confirm enrolment.
What is the difference between pre-screening and screening?
Pre-screening is an early, limited filter designed to find potential matches. Formal screening is the protocol-specific assessment that may include consent, examinations, tests and investigator review before eligibility is confirmed.
Does being identified mean a patient is enrolled?
No. Identification means only that the person may fit some broad requirements. They can decline, fail formal criteria, need reassessment, or be unable to meet the study's practical requirements.
When is informed consent obtained?
The exact timing depends on the study and applicable rules, but informed consent must be obtained before consented research procedures are performed. A preliminary invitation or expression of interest is not the same as informed consent.
From A Potential Match To A Participant
Clinical trial pre-screening works best when it is treated as a transparent handoff rather than a promise of enrolment. Identification finds a possible match. Preliminary review decides whether further contact is sensible. Patient information and consent protect voluntary decision-making. Formal screening tests the protocol requirements. The investigator or authorised site team then confirms whether the person can enrol.
That distinction helps sponsors plan realistic recruitment and helps patients understand what an invitation means. Starting from accurate, current records makes every later stage run more smoothly.
Contact TrialChoices
If your organisation is planning a UK study and wants a faster, GP-led route to suitable participants, TrialChoices can help. Share your protocol synopsis, target population, geography and key inclusion and exclusion criteria, and we will talk you through how pre-screening would work across our GP network.
Call +44 (0)7711 248 610 or email info@trialchoices.org to learn how direct access to millions of UK patients can move your study from potential matches to enrolled participants sooner.
Comments